The immunotherapeutic response is associated with dramatic modifications in the tumor microenvironment (TME). Cytokines and soluble proteins mediate intercellular signaling regulation, modulation of cell metabolism, and TME reprogramming. Cancer cells educate innate immune cells through excreting cytokines, and many metabolites in the TME influence differentiation and recruitment of immunosuppressive cells, thus leading to immunosuppressive TME. Recently, accumulating evidence has identified that modulation of cytokines or soluble mediators in TME could enhance T cell function and might be a promising cancer immunotherapeutic approach. In the era of cancer immunotherapy, cytokines, and soluble mediators not only function as biomarkers of immunosuppressive TME, guiding individualized immunotherapy, but also represent essential therapeutic targets in anti-cancer treatment.
This Research Topic aims to provide a forum to advance research on the role of cytokines or soluble mediators in the reprogramming of tumor microenvironment and to explore novel therapeutic strategies targeting cytokines and soluble mediators.
- Mechanism of metabolites in regulating the tumor microenvironment
- Cytokines or soluble mediators as biomarkers of immunotherapeutic response (including immunochemotherapy, CAR-T, ASCT, and allo-SCT) in hematological malignancies
- Novel therapeutic strategies targeting cytokines or soluble mediators
The immunotherapeutic response is associated with dramatic modifications in the tumor microenvironment (TME). Cytokines and soluble proteins mediate intercellular signaling regulation, modulation of cell metabolism, and TME reprogramming. Cancer cells educate innate immune cells through excreting cytokines, and many metabolites in the TME influence differentiation and recruitment of immunosuppressive cells, thus leading to immunosuppressive TME. Recently, accumulating evidence has identified that modulation of cytokines or soluble mediators in TME could enhance T cell function and might be a promising cancer immunotherapeutic approach. In the era of cancer immunotherapy, cytokines, and soluble mediators not only function as biomarkers of immunosuppressive TME, guiding individualized immunotherapy, but also represent essential therapeutic targets in anti-cancer treatment.
This Research Topic aims to provide a forum to advance research on the role of cytokines or soluble mediators in the reprogramming of tumor microenvironment and to explore novel therapeutic strategies targeting cytokines and soluble mediators.
- Mechanism of metabolites in regulating the tumor microenvironment
- Cytokines or soluble mediators as biomarkers of immunotherapeutic response (including immunochemotherapy, CAR-T, ASCT, and allo-SCT) in hematological malignancies
- Novel therapeutic strategies targeting cytokines or soluble mediators
